Global Medical Tech Becton, Dickinson Expects Lower China Sales, Bioscience And Pharma Market Dynamics To Impact 2025 Organic Revenue Growth

On Thursday, Becton, Dickinson and Company (NYSE:BDX) reported fourth-quarter sales of $5.44 billion, up 6.9% year over year (+7.4% currency-neutral and 6.2% organic), beating the consensus of $5.38 billion.

“In FY24, our team advanced our strategy, continuing to shift our portfolio into higher-growth areas through new innovations and the acquisition of Edwards Lifesciences’ Critical Care product group, while leveraging our BD Excellence system to exceed our margin expansion, earnings and cash flow goals,” said Tom Polen, chairman, CEO and president of BD.

“Our growth strategy remains focused on delivering solutions for our customers that leverage significant shifts ...